Small molecule · Inhibitor of thymidylate synthase (TYMS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GART) · developed by Lilly
Pemetrexed is a folate analog metabolic inhibitor that is taken up into cells and converted to polyglutamate forms, which inhibit thymidylate synthase and GARFT. It also inhibits dihydrofolate reductase, blocking de novo synthesis of thymidine and purine nucleotides needed for cell replication. It is used in non-squamous non-small cell lung cancer and malignant pleural mesothelioma, and is studied in ovarian cancer, urothelial cancer and other solid tumors.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 20, 2026). Read the full label for the exact wording, limitations and safety information.
Advanced MalignanciesNSCLCOvarian CancerSolid TumorsUrothelial Cancer
Updated Oct 25, 2026.